Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TALWIN COMPOUND

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

Standard Dose
325MG;EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TALWIN COMPOUND is listed in Drugs@FDA under application 016891 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; PENTAZOCINE HYDROCHLORIDE Form and strength TABLET;ORAL - 325MG;EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1996-07-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview TALWIN COMPOUND is listed in Drugs@FDA under application 016891 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; PENTAZOCINE HYDROCHLORIDE Form and strength TABLET;ORAL - 325MG;EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1996-07-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
TALWIN COMPOUND (ASPIRIN; PENTAZOCINE HYDROCHLORIDE) | Drug Monograph | MedicHelpline